Kindred Biosciences Director Oleg Nodelman Acquires 85,244 Shares (KIN)
Kindred Biosciences (NYSE:KIN) Director Oleg Nodelman acquired 85,244 shares of Kindred Biosciences stock on the open market in a transaction dated Tuesday, August 26th. The stock was purchased at an average price of $10.50 per share, with a total value of $895,062.00. Following the acquisition, the director now directly owns 50,000 shares of the company’s stock, valued at approximately $525,000. The acquisition was disclosed in a legal filing with the SEC, which is available at this link.
KIN has been the subject of a number of recent research reports. Analysts at BMO Capital Markets cut their price target on shares of Kindred Biosciences from $30.00 to $19.00 in a research note on Thursday, August 21st. Separately, analysts at Leerink Swann cut their price target on shares of Kindred Biosciences from $29.00 to $11.25 in a research note on Thursday, August 21st. Finally, analysts at Roth Capital cut their price target on shares of Kindred Biosciences to $11.50 in a research note on Thursday, August 21st. Two equities research analysts have rated the stock with a buy rating, The stock has a consensus rating of “Buy” and an average target price of $13.92.
Kindred Biosciences (NYSE:KIN) traded up 1.69% on Wednesday, hitting $10.83. 197,687 shares of the company’s stock traded hands. Kindred Biosciences has a 52 week low of $8.75 and a 52 week high of $26.99. The stock’s 50-day moving average is $15.06 and its 200-day moving average is $17.93. The company’s market cap is $213.5 million.
Kindred Biosciences (NYSE:KIN) last released its earnings data on Wednesday, August 13th. The company reported ($0.42) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.35) by $0.07. Analysts expect that Kindred Biosciences will post $-1.75 EPS for the current fiscal year.
Kindred Biosciences, Inc is a development-stage biopharmaceutical company. The Company focused on pets.
Receive News & Ratings for Kindred Biosciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kindred Biosciences Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.